Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase […]